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Abstract
Background
To reduce the risk of drug-induced haemolysis, all patients should be tested for glucose-6-
phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing primaquine
(PQ)-based radical cure for the treatment of vivax malaria. This systematic review and indi-
vidual patient meta-analysis assessed the utility of a qualitative lateral flow assay from
Access Bio/CareStart (Somerset, NJ) (CareStart Screening test for G6PD deficiency) for
the diagnosis of G6PDd compared to the gold standard spectrophotometry (International
Prospective Register of Systematic Reviews [PROSPERO]: CRD42019110994).
Methods and findings
Articles published on PubMed between 1 January 2011 and 27 September 2019 were
screened. Articles reporting performance of the standard CSG from venous or capillary
blood samples collected prospectively and considering spectrophotometry as gold standard
(using kits from Trinity Biotech PLC, Wicklow, Ireland) were included. Authors of articles
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Data Availability Statement: All data included in
the submission can be obtained from the source
fulfilling the inclusion criteria were contacted to contribute anonymized individual data. Mini-
mal data requested were sex of the participant, CSG result, spectrophotometry result in U/
gHb, and haemoglobin (Hb) reading. The adjusted male median (AMM) was calculated per
site and defined as 100% G6PD activity. G6PDd was defined as an enzyme activity of less
than 30%. Pooled estimates for sensitivity and specificity, unconditional negative predictive
value (NPV), positive likelihood ratio (LR+), and negative likelihood ratio (LR−) were calcu-
lated comparing CSG results to spectrophotometry using a random-effects bivariate model.
Of 11 eligible published articles, individual data were available from 8 studies, 6 from
Southeast Asia, 1 from Africa, and 1 from the Americas. A total of 5,815 individual partici-
pant data (IPD) were available, of which 5,777 results (99.3%) were considered for analysis,
including data from 3,095 (53.6%) females. Overall, the CSG had a pooled sensitivity of
0.96 (95% CI 0.90–0.99) and a specificity of 0.95 (95% CI 0.92–0.96). When the prevalence
of G6PDd was varied from 5% to 30%, the unconditional NPV was 0.99 (95% CI 0.94–1.00),
with an LR+ and an LR− of 18.23 (95% CI 13.04–25.48) and 0.05 (95% CI 0.02–0.12),
respectively.
Performance was significantly better in males compared to females (p = 0.027) but did
not differ significantly between samples collected from capillary or venous blood (p = 0.547).
Limitations of the study include the lack of wide geographical representation of the included
data and that the CSG results were generated under research conditions, and therefore
may not reflect performance in routine settings.
Conclusions
The CSG performed well at the 30% threshold. Its high NPV suggests that the test is suit-
able to guide PQ treatment, and the high LR+ and low LR− render the test suitable to confirm
and exclude G6PDd. Further operational studies are needed to confirm the utility of the test
in remote endemic settings.
Author summary
Why was this study done?
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) is the key determi-
nant of severe haemolysis following primaquine (PQ)-based radical cure of vivax
malaria.
• A widely available reliable point-of-care diagnostic for G6PDd will improve patient
safety of PQ treatment.
• A rapid diagnostic G6PD test from Access Bio (Somerset, NJ) has operational character-
istics that render the test suitable for use at the bedside.
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What did the researchers do and find?
• We reviewed the literature systematically and identified studies that had evaluated the
G6PD test and compared results with those generated by the gold standard
spectrophotometry.
• Individual participant data (IPD), available from 5,777 participants, demonstrated that
the test had a 96% sensitivity for detecting G6PD-deficient individuals with a specificity
of 95%.
What do these findings mean?
• Under research conditions, the G6PD test reliably confirms and excludes G6PDd in
patients with G6PD activity of less than 30% (the most widely applied cut-off activity to
guide PQ-based radical cure).
• These findings will have to be confirmed in routine clinical settings.
Introduction
Radical cure of Plasmodium vivax and P. ovale malaria requires killing of both the blood and
liver stages of the parasite to prevent relapsing malaria and reduce ongoing transmission [1].
Primaquine (PQ) has been used for over 65 years and is currently the only widely available
hypnozoitocidal drug for P. vivax and P. ovale. PQ has to be administered in combination with
a blood schizontocidal agent over 7 to 14 days to clear hypnozoites [2–6]. While PQ is tolerated
in most patients, it can cause haemolysis in patients with glucose-6-phosphate dehydrogenase
deficiency (G6PDd), the severity of which is dependent on the underlying genetic variant, the
dose of PQ administered, and the age of the patient’s red blood cell (RBC) population [7,8].
To date, 215 genotypes conferring different degrees of G6PDd have been described, and
these are most prevalent in areas of past and present malaria endemicity [9–11]. The G6PD
gene is located on the X chromosome (Xq28), therefore males are either hemizygous G6PD
deficient or G6PD normal, whereas females can be homozygous G6PD deficient, G6PD nor-
mal, or heterozygous for the gene. In heterozygous females, one copy of the G6PD gene is ran-
domly inactivated through a process called lyonization; accordingly, heterozygous females
harbour 2 distinct groups of RBCs, a G6PD normal and a G6PD-deficient one [12]. Depending
on the ratio of G6PD-normal to G6PD-deficient RBCs, heterozygous females may be at a risk
of severe drug-induced haemolysis [13,14].
To reduce the risk of drug-induced haemolysis, WHO recommends that patients be tested
routinely for G6PDd prior to administration of PQ-based radical cure [4]. The gold standard
method for measuring G6PD activity is quantitative spectrophotometry [15,16], but this
method is expensive and requires laboratory facilities that are often unavailable in malaria-
endemic communities, especially in remote areas. The fluorescent spot test (FST) is a qualita-
tive alternative; however, it also requires laboratory infrastructure and extensive training for
reliable interpretation [17,18]. In 2011, Access Bio (Somerset, NJ) introduced a qualitative, lat-
eral-flow point-of-care assay (CareStart screening test for G6PDd; CSG) [19]. The aim of this
article was to undertake a meta-analysis of published studies to determine the performance of
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the assay in a variety of populations at risk of drug-induced haemolysis (International Prospec-
tive Register of Systematic Reviews [PROSPERO]: CRD42019110994).
Methods
Search strategy and eligibility criteria
A PubMed search was undertaken for relevant articles published in English between 1 January
2011, when the test was first introduced [19], and 27 of September 2019. The search terms
applied were “G6PD AND (rapid diagnostic test OR carestart)”. Identified articles were first
screened for eligibility by title, abstract, and then by the full text by 3 study authors (BL, AWS,
and HR) independently. Reference sections of identified articles were screened for additional
relevant articles. Eligible articles reported performance indicators of the CSG from samples
collected prospectively. Articles describing prototypes of the CSG were excluded. Only studies
comparing the CSG results to the gold standard spectrophotometry, using kits from Trinity
Biotech PLC (Wicklow, Ireland), were included. Studies were included irrespective of whether
blood was collected from capillary or venous sampling.
Corresponding authors of identified articles were contacted and asked to provide anon-
ymized individual participant data (IPD). All corresponding authors were contacted a mini-
mum of 3 times before the study was excluded. Minimal data requested included the sex of the
participant, CSG result, spectrophotometry result in U/gHb, and corresponding haemoglobin
measurement in U/dL. Data were entered into a customized Excel database (Microsoft Corpo-
ration, Redmond, WA) and analysed using Stata software version 14 (release 14; StataCorp,
College Station, TX). Analysis was done primarily using the Midas package.
Data preparation
Invalid CSG results were excluded from the analysis. Spectrophotometry results that were
missing or extreme (>25 U/gHb) were excluded from analyses because these readings sug-
gested a procedural or data error. Some studies reported an intermediate CSG result; in clinical
use, these are more likely to be considered G6PDd results and were defined accordingly. One
article reported the results of 2 separate evaluation studies from Laos and Cambodia [20];
because the applied cut-off activities and reported performance were distinct for each country,
the results are reported separately.
The adjusted male median (AMM) was calculated from spectrophotometry results sepa-
rately for each study site and defined as 100% G6PD activity [16]. Because some studies applied
different definitions of 100% G6PD activity (for example, by considering genotype [21]), the
definitions within this study and the original source articles may sometimes differ. Studies
reported spectrophotometry results either from venous and/or capillary blood, and the source
of blood could have affected spectrophotometry measurements. One study measured G6PD
activity in paired capillary and venous samples by spectrophotometry [21], and the results
were compared for significant differences using the Wilcoxon signed-rank test.
Spectrophotometry provides a quantitative result; following the current informal cut-off to
guide PQ-based radical cure [15], and the intended cut-off of the CSG [17,20], any sample
with less than 30% of the AMM was defined as G6PDd. Study-specific performance was calcu-
lated following standard formulae [16,22,23], by comparing the CSG against the reference
method spectrophotometry. A positive result was defined as a G6PDd outcome and a negative
result as a G6PD normal outcome. Results from the CSG were then classified as true positive
(TP), true negative (TN), false positive (FP), and false negative (FN) with reference to the
results of spectrophotometry.
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Data analysis
To calculate the pooled estimates for sensitivity and specificity, a 2-level model with indepen-
dent binomial distributions was fitted for the TPs and TNs conditional on the sensitivity and
specificity in each study, and a bivariate normal model for the logit transformations of the sen-
sitivity and specificity between the studies was created [24]. A summary receiver operator
characteristic (SROC) curve was constructed, and the area under the curve (AUC) was calcu-
lated to determine overall test performance.
Unconditional predictive values were calculated for G6PDd prevalence of 5% to 30%
reflecting G6PDd prevalence within most malaria-affected populations [25]. Likelihood ratios
are a convenient method to determine the usability of a diagnostic test. In the case of the CSG,
the positive likelihood ratio (LR+) describes how many times more likely a G6PDd test result
is to occur in a G6PD-deficient individual compared to in a G6PD-normal individual. The
negative likelihood ratio (LR−) is defined as the inverse of this, or how much less likely a
G6PD-deficient result will occur in a G6PD-normal person compared to a G6PD-deficient
individual [26]. In general, tests with an LR+ above 10 are considered suitable for the diagnosis
of a condition, and an LR− of less than 0.1 is considered suitable to exclude a condition [27].
The LR+ and LR− were calculated, and the practical utility of the CSG was evaluated by con-
structing likelihood ratio diagrams. The quality of the included publications was assessed
using the QUADAS-2 tool [28].
Model validation
I2 was calculated as a measure of heterogeneity for sensitivity and specificity. Publication bias
was assessed by a funnel plot, and a linear regression model was fitted to the log odds ratio of
the inverse root of effective sample sizes as a test for funnel plot asymmetry.
Sensitivity analyses
We tested whether the sensitivity and the specificity of the tests varied by type of blood col-
lected (capillary or venous) and sex by fitting separate multilevel models. In the first, we
included a covariate for blood type and allowed both sensitivity and specificity to vary by
blood type; we then repeated the analysis by instead including a covariate for sex. Each of these
models was compared to a model without covariates using a likelihood ratio test. Additional
sensitivity analyses were undertaken in which the pooled performance was recalculated
excluding studies that were at high risk of bias due to participant selection or laboratory meth-
ods. The pooled performance was recalculated applying a pooled AMM across all included
studies rather than the study-specific AMM. In response to a reviewer’s request, the analysis
was repeated including all data as well as the aggregated data extracted from eligible articles for
which individual patients’ data were not available. The definition of TP, TN, FP, and FN for
articles in which no IPD were available was based on definitions applied in the respective stud-
ies. Whenever a discrepancy between reported performance and numbers of TPs and FPs and
TNs and FNs was found, the latter was considered.
Results
Identified studies and participants
A total of 42 articles were identified in the literature review, of which 11 met the inclusion and
exclusion criteria. Individual data were available from 8 studies (Fig 1) enrolling a total of
5,815 participants with paired CSG and spectrophotometry measurements (S1 Table).
A meta-analysis of the performance of the Access Bio/Care Start RDT for the detection of G6PD deficiency
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All of the studies included were undertaken between 2014 and 2018. Six studies were con-
ducted in Southeast Asia [20,21,29–32], one in Africa [33], and one in the Americas [34]. In
total, 3 studies (4 countries, 2,845 participants) assessed G6PD status from capillary blood
[20,31,33] and 3 from venous blood (3 countries, 2,066 participants) [30,32,34]. In 1 study,
CSG and spectrophotometry were performed on both venous and capillary samples [21], and
in 1 study CSG was performed on both venous and capillary samples; however, spectropho-
tometry was only performed on capillary blood [29] (Table 1). Results from 14 (0.2%)
Fig 1. Flow chart on article selection.
https://doi.org/10.1371/journal.pmed.1002992.g001
Table 1. Origin, source of blood, and results included.
Article Blood Country Original sample size G6PD > 25 U/gHb or missing (%) Invalid CSG result (%) Total included (%)
Bancone, 2015� [21] Capillary Thailand 150 0 (0.0) 12 (8.0) 138 (92.0)
Bancone, 2015� [21] Venous Thailand 150 0 (0.0) 1 (0.6) 149 (99.3)
Espino, 2016�� [29] Capillary Philippines 302 1 (0.3) 0 (0.0) 301 (99.7)
Espino, 2016�� [29] Venous Philippines 302 1 (0.3) 0 (0.0) 301 (99.7)
Henriques, 2018��� [20] Capillary Cambodia 505 0 (0.0) 7 (1.4) 498 (98.6)
Henriques, 2018��� [20] Capillary Laos 757 4 (0.6) 4 (0.6) 749 (98.9)
Oo, 2016 [30] Venous Myanmar 1,000 0 (0.0) 0 (0.0) 1,000 (100.0)
Roca-Feltrer, 2014 [31] Capillary Cambodia 938 5 (0.5) 0 (0.0) 933 (99.5)
Roh, 2016, Uganda [33] Capillary Uganda 645 2 (0.3) 0 (0.0) 643 (99.7)
Satyagraha, 2016 [32] Venous Indonesia 610 1 (0.2) 0 (0.0) 609 (99.8)
von Fricken, 2014 [34] Venous Haiti 456 0 (0.0) 0 (0.0) 456 (100.0)
Total 5,815 14 (0.2) 24 (0.4) 5,777 (99.3)
�Paired CSG and spectrophotometry results from venous and capillary blood.
��Paired CSG results from venous and capillary blood, spectrophotometry results from venous blood.
���Same publication but different sites.
Abbreviations: CSG, CareStart Screening test for G6PD deficiency; G6PD, glucose-6-phosphate dehydrogenase
https://doi.org/10.1371/journal.pmed.1002992.t001
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participants were excluded because the spectrophotometry result was missing or had an
extreme value (>25 U/gHb), and results from 24 (0.4%) participants were excluded due to an
invalid CSG result. A total of 5,777 (99.3%) results were included in the analysis (Table 1), of
which 3,095 (53.6%) were from females. The majority of samples were collected from healthy
volunteers (Table 2).
Definition of 100% G6PD activity
In the study with paired spectrophotometry measures of patients with both capillary and
venous sampling, there was no significant difference in G6PD activity (p = 0.292) [21]. Results
for capillary and venous spectrophotometry were therefore pooled. The site-specific AMM
ranged from 6.6 U/gHb to 12.3 U/gHb. When results were pooled across all studies, the overall
AMM was 9.2 U/gHb (interquartile range [IQR] 7.2–11.5) (Table 2).
Table 2. Details on studies included.
Article Blood Country Study population n With
malaria
(%)�
Females
included
(%)
Males
included
(%)
Calculated local
AMM (100% G6PD
activity) in U/gHb;
G6PD activity at
30%��
n of Study
population included
with <30% G6PD
activity based on
local AMM (%)
n of Study
population included
with <30% G6PD
activity based on
pooled AMM (%)
Bancone,
2015 [21]
Capillary Thailand Healthy volunteers 0 (0.0) 95 (68.8) 43 (31.2) 6.6; 2.0 41 (29.7) 44 (31.9)
Bancone,
2015 [21]
Venous Thailand Healthy volunteers 0 (0.0) 99 (66.4) 50 (33.6) 6.6; 2.0 45 (30.2) 51 (34.2)
Espino, 2016
[29]
Capillary Philippines High school students
from cross-sectional
survey
Not
provided
197 (65.5) 104 (34.6) 11.1; 3.3 17 (5.7) 16 (5.3)
Espino, 2016
[29]
Venous Philippines High school students
from cross-sectional
survey
Not
provided
197 (65.5) 104 (34.6) 11.1; 3.3 17 (5.7) 16 (5.3)
Henriques,
2018 [20]
Capillary Cambodia Participants of cross-
sectional survey
Not
provided
248 (49.8) 250 (50.2) 7.6; 2.3 117 (23.5) 124 (24.9)
Henriques,
2018 [20]
Capillary Laos Purposively selected
community members
Not
provided
366 (48.9) 383 (51.1) 11.5; 3.5 39 (5.2) 38 (5.07)
Oo, 2016
[30]
Venous Myanmar Healthy volunteers 0 (0.0) 476 (47.6) 524 (52.4) 8.3; 2.5 68 (6.8) 68 (6.8)
Roca-Feltrer,
2014 [31]
Capillary Cambodia Adults >18 years,
nonpregnant from
cross-sectional
survey
0 (0.0) 484 (51.9) 449 (48.1) 12.0; 3.6 74 (7.9) 70 (7.5)
Roh, 2016,
Uganda [33]
Capillary Uganda Children 6–59
months from cross-
sectional survey
(3.5% with
microscopic malaria)
22 (3.4) 317 (49.3) 326 (50.7) 6.4; 1.9 10 (1.6) 24 (3.73)
Satyagraha,
2016 [32]
Venous Indonesia All ages from cross-
sectional survey
(2.5% with malaria)
15 (2.5) 349 (57.3) 260 (42.7) 9.3; 2.8 30 (4.9) 30 (4.9)
von Fricken,
2014 [34]
Venous Haiti Primary school
children from cross-
sectional survey
Not
provided
267 (58.6) 189 (41.5) 9.1 46 (10.1) 46 (10.1)
�Based on publication.
��Calculated cut-offs and cut-offs published in source article do not necessarily match due to different definitions.
Abbreviations: AMM, adjusted male median; G6PD, glucose-6-phosphate dehydrogenase
https://doi.org/10.1371/journal.pmed.1002992.t002
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Pooled performance
The pooled sensitivity was 0.96 (95% CI 0.90–0.99) (Fig 2), and the specificity was 0.95 (95%
CI 0.92–0.96) (Fig 3). The number of invalid results was significantly higher for capillary sam-
ples (12/3,274) compared to venous samples (2/2,517, p = 0.022) (Table 1); the AUC of the
SROC was 0.98 (95% CI 0.97–0.99) (S1 Fig).
Fig 2. Forest plot: Sensitivity. Threshold for G6PDd is calculated based on the site-specific AMM. Study ID is
identified by first author, country of sample collection, and type of blood used. AMM, adjusted male median; G6PDd,
glucose-6-phosphate dehydrogenase deficiency.
https://doi.org/10.1371/journal.pmed.1002992.g002
Fig 3. Forest plot: Specificity. Threshold for G6PDd is calculated based on the site-specific AMM. Study ID is
identified by first author, country of sample collection, and type of blood used. AMM, adjusted male median; G6PDd,
glucose-6-phosphate dehydrogenase deficiency.
https://doi.org/10.1371/journal.pmed.1002992.g003
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Utility of the CSG
When the prevalence of G6PDd was varied from 5% to 30%, the unconditional negative pre-
dictive value (NPV) was 0.97 (95% CI:0.94–1.00), and the positive predictive value (PPV) was
0.76 (95% CI 0.72–0.81). The LR+ and LR− were 18.2 (95% CI 13.0–25.5) and 0.05 (95% CI
0.02–0.12), respectively (S2 Fig).
Publication bias
Three of the 11 eligible studies (enrolling 1,280 participants from Brazil, Yemen, and Ghana)
were not included because the corresponding authors did not reply [35–37]. These studies had
a higher proportion of malaria patients. The characteristics of studies included and excluded
in the individual data analysis are presented in S2 Table. No significant publication bias was
detected among included studies (p = 0.41); 3 studies were identified as yielding a high risk of
bias, 2 due to purposive selection of participants [20,21] and 1 due to lack of temperature-con-
trolled spectrophotometry [34] (Fig 4, S3 Fig).
Sensitivity analyses
In the a priori sensitivity analyses, the pooled performance did not vary significantly irrespec-
tive of whether capillary or venous blood was collected (p = 0.547). For capillary samples, the
sensitivity was 0.99 (95% CI 0.80–1.00), and specificity was 0.94 (95% CI 0.90–0.97) compared
to 0.93 (95% CI 0.87–0.96) and 0.94 (95% CI 0.92–0.96), respectively, for venous samples.
However, performance differed significantly between males and females (p = 0.027). In males,
the sensitivity was 0.97 (95% CI 0.92–0.99), and specificity was 0.98 (95% CI 0.96–0.99), signif-
icantly higher than in females, who had a sensitivity of 0.92 (95% CI 0.80–0.97) and a specific-
ity of 0.93 (95% CI 0.89–0.96) (Table 3).
When 2 studies enrolling purposively selected participants were excluded, the pooled perfor-
mance was slightly lower (sensitivity 0.95, 95% CI 0.86–0.99; specificity 0.94, 95% CI 0.93–0.96)
[20,21]. When one study using venous samples in which spectrophotometry was not tempera-
ture controlled was excluded, the overall pooled performance was unchanged (sensitivity 0.96,
95% CI 0.89–0.98; specificity 0.95, 95% CI 0.93–0.96), although the performance for venous sam-
ples was slightly lower (sensitivity 0.95, 95% CI 0.89–0.98; specificity 0.95, 95% CI 0.92–0.97).
When the analysis was repeated using an AMM derived from pooled spectrophotometry
data rather than the site-specific AMM, the pooled performance did not differ (sensitivity 0.96,
95% CI 0.89–0.98; specificity 0.95, 95% CI 0.93–0.96) (Table 3 and S4 Fig). When aggregated
data were included from the 3 studies that fulfilled the inclusion criteria, but for which no IPD
were available, the performance did not change (Table 3, S5 Fig).
Fig 4. Qualitative assessment of included studies (QUADAS2). QUADAS2, Quality Assessment of Diagnostic Accuracy
Studies.
https://doi.org/10.1371/journal.pmed.1002992.g004
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Discussion
In this meta-analysis, we observed an overall sensitivity and specificity of the CSG of more
than 95%; the NPV was almost 100% across a wide range of G6PDd prevalences. The high
LR+ and low LR− suggest that the CSG is suitable for confirmation as well as exclusion of
G6PDd at a 30% threshold level.
The CSG performed significantly better in males compared to females. The CSG performs best
at an approximate 30% cut-off activity [20]; however, the absolute cut-off of the CSG and the
absolute cut-off calculated from spectrophotometry do not necessarily match. Since males are
either hemizygous normal or deficient, their enzyme activity will be either below or well above the
30% cut-off, and small discrepancies between the 2 thresholds will not affect the calculated perfor-
mance. However, females can be either homozygous or heterozygous for the G6PD gene, the latter
manifesting phenotypically with enzyme activities ranging from almost normal to G6PD deficient
[12–14]. Therefore, in heterozygous females, small differences between the inherent test and the
calculated cut-off activity will affect the test’s performance adversely.
The performance of the CSG was slightly better in samples collected from capillary com-
pared to venous blood, although this did not reach statistical significance. However, the overall
performance was more reliable in studies using venous blood, which had a lower number of
invalid results. Bancone and colleagues previously compared CSG results from paired venous
and capillary samples, with 11% discrepancy between samples, with a sensitivity at the 30%
threshold of 100% in capillary samples compared to 89% in venous samples [21]. In the same
study, the authors also correlated their findings with haematological parameters and found
that RBC concentration, haemoglobin, haematocrit, mean corpuscular volume, and platelet
count varied slightly between venous and capillary samples; however, they concluded that
these differences were unlikely to have a major effect on the performance of the CSG [21]. In
contrast, a study conducted by Espino and colleagues reported lower sensitivities for diagnos-
ing deficiency at the 30% threshold among capillary samples (69% sensitivity) compared to
their paired venous counterparts (94% sensitivity) [29].
Despite the significantly higher number of invalid results, the CSG is more likely to be per-
formed on capillary blood from a finger prick, following the same procedures as for malaria rapid
diagnostic tests. The observed good performance of the CSG on capillary blood is therefore reas-
suring; the pooled sensitivity is similar to the widely used FST [38]. While the CSG and the FST
can be applied to screen patients for G6PDd prior to administering PQ, the recommended criteria
for the recently licensed 8-aminoquinoline drug tafenoquine (TQ) are more stringent and require
diagnosis of G6PDd at a 70% threshold, which requires a quantitative assay [39,40].
Table 3. Results of pooled and sensitivity analysis.
Analysis Sensitivity (95% CI) Specificity (95% CI) Sample size
Primary analysis 0.96 (0.90–0.99) 0.95 (0.92–0.96) 5,777
Capillary only 0.99 (0.80–1.00) 0.94 (0.90–0.97) 3,262
Venous only 0.93 (0.87–0.96) 0.94 (0.90–0.97) 2,515
Males only 0.97 (0.92–0.99) 0.98 (0.96–0.99) 2,682
Females only 0.92 (0.80–0.97) 0.93 (0.89–0.96) 3,095
Excluding studies with purposively selected participants 0.95 (0.86–0.99) 0.94 (0.93–0.96) 4,243
Excluding studies without temperature-controlled spectrophotometry 0.96 (0.89–0.98) 0.95 (0.93–0.96) 5,321
Applying pooled AMM 0.96 (0.89–0.98) 0.95 (0.93–0.96) 5,777
Considering aggregate data from all eligible studies 0.96 (0.90–0.99) 0.95 (0.92–0.96) 7,057
Abbreviation: AMM, adjusted male median
https://doi.org/10.1371/journal.pmed.1002992.t003
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In reality, G6DP testing is rarely available in malaria-endemic communities, and therefore
PQ is often not prescribed due to fear of inducing haemolysis in vulnerable patients [2]. The
availability of a robust point-of-care G6PD test to screen patients prior to treatment provides a
significant advance that will enhance the uptake of radical cure into routine practice. Unfortu-
nately, the CSG does not have a control line, and this has implications for implementation into
routine practice. Previous studies have shown that, at a cost of US$1.75, the use of the CSG is a
cost-effective strategy at enhancing safe and effective radical cure with PQ [41].
Limitations
Our study has a number of limitations. The geographical spread of results included was lim-
ited, with most studies being conducted in Southeast Asia. It is likely that the performance,
including PPV and NPV of the tests, will vary with the local context, including the prevalence
and variants of G6PDd and the training and education of the clinic staff.
Only a few data variables were collated from all studies, and therefore our covariate analysis
was limited to the haemoglobin concentration, the sex of the participant, and the country of
sample collection. Other factors that may also have influenced the test results could have
included batch to batch variability in test kits, the temperature at which the tests were per-
formed, and training and ability of individuals undertaking the tests.
Spectrophotometry remains the gold standard for the diagnosis of G6PDd and was used as
the reference for the current analysis [16]. Alternative approaches, such as molecular analysis
for G6PD variants correlate poorly with G6PD phenotype, precluding use of this approach as
reliable reference [33,42–44]. In a comparison between Trinity spectrophotometry kits, con-
sidered for this analysis, and another spectrophotometry kit (Pointe Scientific, Canton, MI),
both assays showed a very good correlation (r = 0.9799, p< 0.001) [45].
The AMM was calculated for each site specifically; consequently, the absolute cut-off activ-
ity in U/gHb of the reference method spectrophotometry varied across sites. To assess whether
this had an impact on the pooled performance, the analysis was repeated calculating a univer-
sal AMM across all sites; reassuringly, the results of the pooled performance did not differ.
IPD from 3 eligible studies, enrolling 1,280 participants, were not available [35–37]. In con-
trast to the included studies, the proportion of malaria patients among the excluded studies
was higher. It is possible that malaria influences G6PD activity, although it is unlikely that this
would have impacted the observed performance because CSG and spectrophotometry testing
were done on the same sample.
Reassuringly, when the analysis was repeated including aggregated data, the test performance
did not change. Finally, all studies included were performed under research conditions and by
well-trained study staff; in real-life settings, the performance of the CSG could be lower.
Conclusion
The results from this pooled analysis suggest that the CSG provides a reliable method to iden-
tify individuals with less than 30% G6PD enzyme activities; based on these findings, the test is
suitable for introduction into routine treatment prior to PQ but not TQ treatment. Further
operational research is required to assess how the test performs under real-life conditions.
Supporting information
S1 PRISMA Checklist. PRISMA IPD checklist. PRISMA, Preferred Reporting Items for Sys-
tematic reviews and Meta-Analyses.
(DOCX)
A meta-analysis of the performance of the Access Bio/Care Start RDT for the detection of G6PD deficiency
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002992 December 13, 2019 11 / 15
S1 Table. Test methods applied.
(DOCX)
S2 Table. Details on studies not included.
(DOCX)
S3 Table. Contact details from which data were obtained.
(DOCX)
S1 Fig. Summary ROC. ROC, Receiver Operating Characteristics curve.
(TIF)
S2 Fig. Likelihood ratio scatter diagram.
(TIF)
S3 Fig. Deeks’ funnel plot asymmetry test.
(TIF)
S4 Fig. Forest plot: Sensitivity and specificity, pooled AMM. Threshold for G6PDd is calcu-
lated based on the pooled AMM.
(TIF)
S5 Fig. Forest plot: Sensitivity and specificity, all studies fitting the inclusion criteria.
Threshold for G6PDd is based on definitions provided from aggregate data (first 3 studies
from top) and calculated based on the site-specific AMM for IPD (all other studies). Study ID
is identified by first author, country of sample collection, and type of blood used.
(TIF)
Acknowledgments
We would like to thank all participants of the studies included, as well as all staff that contrib-
uted to the primary articles included. We would also like to thank Mr. Sharif Hossain, who
provided statistical advice.
Author Contributions
Conceptualization: Benedikt Ley, Ari Winasti Satyagraha.
Data curation: Benedikt Ley, Ari Winasti Satyagraha, Hisni Rahmat.
Formal analysis: Benedikt Ley, Amalia Karahalios.
Investigation: Benedikt Ley.
Methodology: Benedikt Ley.
Project administration: Benedikt Ley.
Supervision: Benedikt Ley.
Validation: Benedikt Ley, Ari Winasti Satyagraha, Hisni Rahmat, Michael E. von Fricken,
Nicholas M. Douglas, Daniel A. Pfeffer, Fe Espino, Lorenz von Seidlein, Gisela Henriques,
Nwe Nwe Oo, Didier Menard, Sunil Parikh, Germana Bancone, Amalia Karahalios, Ric N.
Price.
Visualization: Benedikt Ley.
Writing – original draft: Benedikt Ley.
A meta-analysis of the performance of the Access Bio/Care Start RDT for the detection of G6PD deficiency
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002992 December 13, 2019 12 / 15
Writing – review & editing: Benedikt Ley, Ari Winasti Satyagraha, Hisni Rahmat, Michael E.
von Fricken, Nicholas M. Douglas, Daniel A. Pfeffer, Fe Espino, Lorenz von Seidlein, Gisela
Henriques, Nwe Nwe Oo, Didier Menard, Sunil Parikh, Germana Bancone, Amalia Kara-
halios, Ric N. Price.
References
1. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign.
The American journal of tropical medicine and hygiene. 2007; 77(6 Suppl):79–87. PMID: 18165478
2. Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency
testing: Divergent policies and practices in malaria endemic countries. PLoS neglected tropical dis-
eases. 2018; 12(4):e0006230. https://doi.org/10.1371/journal.pntd.0006230 PMID: 29672516
3. ARMY giving primaquine treatment to all returning servicemen. Public Health Rep. 1952; 67(2):178–9.
PMID: 14900346
4. WHO. Guidelines for the treatment of malaria - 3rd Edition. Switzerland: WHO; 2015.
5. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, et al. Primaquine radical cure of
Plasmodium vivax: a critical review of the literature. Malaria journal. 2012; 11:280. https://doi.org/10.
1186/1475-2875-11-280 PMID: 22900786
6. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004; 39(9):1336–45. https://doi.
org/10.1086/424663 PMID: 15494911
7. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malaria journal. 2014; 13:418.
https://doi.org/10.1186/1475-2875-13-418 PMID: 25363455
8. Commons RJ, Simpson JA, Thriemer K, Humphreys GS, Abreha T, Alemu SG, et al. The effect of chlo-
roquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance
Network systematic review and individual patient pooled meta-analysis. The Lancet Infectious dis-
eases. 2018; 18(9):1025–34. https://doi.org/10.1016/S1473-3099(18)30348-7 PMID: 30033231
9. WHO. Guide to G6PD deficiency rapid diagnostic testing to support P. vivax radical cure. In: Organiza-
tion WH, editor. Geneva, switzerland2018.
10. Gomez-Manzo S, Marcial-Quino J, Vanoye-Carlo A, Serrano-Posada H, Ortega-Cuellar D, Gonzalez-
Valdez A, et al. Glucose-6-Phosphate Dehydrogenase: Update and Analysis of New Mutations around
the World. Int J Mol Sci. 2016; 17(12).
11. Minucci A, Moradkhani K, Hwang MJ, Zuppi C, Giardina B, Capoluongo E. Glucose-6-phosphate dehy-
drogenase (G6PD) mutations database: review of the "old" and update of the new mutations. Blood
Cells Mol Dis. 2012; 48(3):154–65. https://doi.org/10.1016/j.bcmd.2012.01.001 PMID: 22293322
12. Luzzatto L. Glucose 6-phosphate dehydrogenase deficiency: from genotype to phenotype. Haematolo-
gica. 2006; 91(10):1303–6. PMID: 17018377
13. Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, et al. Haemolysis in G6PD Heterozy-
gous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of
Radical Curative Regimens. PLoS medicine. 2017; 14(2):e1002224. https://doi.org/10.1371/journal.
pmed.1002224 PMID: 28170391
14. Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-induced haemolysis in females het-
erozygous for G6PD deficiency. Malaria journal. 2018; 17(1):101. https://doi.org/10.1186/s12936-018-
2248-y PMID: 29499733
15. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge
gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical
deployment of 8-aminoquinoline treatment regimens: a workshop report. Malaria journal. 2013; 12:112.
https://doi.org/10.1186/1475-2875-12-112 PMID: 23537118
16. Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, et al. G6PD testing in support
of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malaria journal.
2013; 12:391. https://doi.org/10.1186/1475-2875-12-391 PMID: 24188096
17. Ley B, Luter N, Espino FE, Devine A, Kalnoky M, Lubell Y, et al. The challenges of introducing routine
G6PD testing into radical cure: a workshop report. Malaria journal. 2015; 14:377. https://doi.org/10.
1186/s12936-015-0896-8 PMID: 26416229
18. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood. 2008; 111
(1):16–24. https://doi.org/10.1182/blood-2007-04-077412 PMID: 18156501
19. Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, et al. Performance of the CareStart G6PD defi-
ciency screening test, a point-of-care diagnostic for primaquine therapy screening. PloS one. 2011; 6
(12):e28357. https://doi.org/10.1371/journal.pone.0028357 PMID: 22164279
A meta-analysis of the performance of the Access Bio/Care Start RDT for the detection of G6PD deficiency
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002992 December 13, 2019 13 / 15
20. Henriques G, Phommasone K, Tripura R, Peto TJ, Raut S, Snethlage C, et al. Comparison of glucose-6
phosphate dehydrogenase status by fluorescent spot test and rapid diagnostic test in Lao PDR and
Cambodia. Malaria journal. 2018; 17(1):243. https://doi.org/10.1186/s12936-018-2390-6 PMID:
29929514
21. Bancone G, Chu CS, Chowwiwat N, Somsakchaicharoen R, Wilaisrisak P, Charunwatthana P, et al.
Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD
point-of-care tests. The American journal of tropical medicine and hygiene. 2015; 92(4):818–24. https://
doi.org/10.4269/ajtmh.14-0696 PMID: 25646252
22. Banoo S, Bell D, Bossuyt P, Herring A, Mabey D, Poole F, et al. Evaluation of diagnostic tests for infec-
tious diseases: general principles. Nature reviews Microbiology. 2006; 4(12 Suppl):S20–32. https://doi.
org/10.1038/nrmicro1570 PMID: 17366684
23. Ley B, Bancone G, von Seidlein L, Thriemer K, Richards JS, Domingo GJ, et al. Methods for the field
evaluation of quantitative G6PD diagnostics: a review. Malaria journal. 2017; 16(1):361. https://doi.org/
10.1186/s12936-017-2017-3 PMID: 28893237
24. Riley RD, Dodd SR, Craig JV, Thompson JR, Williamson PR. Meta-analysis of diagnostic test studies
using individual patient data and aggregate data. Statistics in medicine. 2008; 27(29):6111–36. https://
doi.org/10.1002/sim.3441 PMID: 18816508
25. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence
and estimates of affected populations in malaria endemic countries: a geostatistical model-based map.
PLoS medicine. 2012; 9(11):e1001339. https://doi.org/10.1371/journal.pmed.1001339 PMID:
23152723
26. McGee S. Simplifying likelihood ratios. J Gen Intern Med. 2002; 17(8):646–9. https://doi.org/10.1046/j.
1525-1497.2002.10750.x PMID: 12213147
27. Simundic AM. Measures of Diagnostic Accuracy: Basic Definitions. EJIFCC. 2009; 19(4):203–11.
PMID: 27683318
28. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised
tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine. 2011; 155
(8):529–36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009 PMID: 22007046
29. Espino FE, Bibit JA, Sornillo JB, Tan A, von Seidlein L, Ley B. Comparison of Three Screening Test Kits
for G6PD Enzyme Deficiency: Implications for Its Use in the Radical Cure of Vivax Malaria in Remote
and Resource-Poor Areas in the Philippines. PloS one. 2016; 11(2):e0148172. https://doi.org/10.1371/
journal.pone.0148172 PMID: 26849445
30. Oo NN, Bancone G, Maw LZ, Chowwiwat N, Bansil P, Domingo GJ, et al. Validation of G6PD Point-of-
Care Tests among Healthy Volunteers in Yangon, Myanmar. PloS one. 2016; 11(4):e0152304. https://
doi.org/10.1371/journal.pone.0152304 PMID: 27035821
31. Roca-Feltrer A, Khim N, Kim S, Chy S, Canier L, Kerleguer A, et al. Field trial evaluation of the perfor-
mances of point-of-care tests for screening G6PD deficiency in Cambodia. PloS one. 2014; 9(12):
e116143. https://doi.org/10.1371/journal.pone.0116143 PMID: 25541721
32. Satyagraha AW, Sadhewa A, Elvira R, Elyazar I, Feriandika D, Antonjaya U, et al. Assessment of Point-
of-Care Diagnostics for G6PD Deficiency in Malaria Endemic Rural Eastern Indonesia. PLoS neglected
tropical diseases. 2016; 10(2):e0004457. https://doi.org/10.1371/journal.pntd.0004457 PMID:
26894297
33. Roh ME, Oyet C, Orikiriza P, Wade M, Mwanga-Amumpaire J, Boum Y 2nd, et al. Screening for Glu-
cose-6-Phosphate Dehydrogenase Deficiency Using Three Detection Methods: A Cross-Sectional Sur-
vey in Southwestern Uganda. The American journal of tropical medicine and hygiene. 2016; 95
(5):1094–9. https://doi.org/10.4269/ajtmh.16-0552 PMID: 27672207
34. von Fricken ME, Weppelmann TA, Eaton WT, Masse R, Beau de Rochars MV, Okech BA. Performance
of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in Gressier, Haiti.
The American journal of tropical medicine and hygiene. 2014; 91(1):77–80. https://doi.org/10.4269/
ajtmh.14-0100 PMID: 24778197
35. Brito MA, Peixoto HM, Almeida AC, Oliveira MR, Romero GA, Moura-Neto JP, et al. Validation of the
rapid test Carestart(tm) G6PD among malaria vivax-infected subjects in the Brazilian Amazon. Rev Soc
Bras Med Trop. 2016; 49(4):446–55. https://doi.org/10.1590/0037-8682-0134-2016 PMID: 27598631
36. Abdul-Ghani R, Mahdy MA, Saif-Ali R, Alkubati SA, Alqubaty AR, Al-Mikhlafy AA, et al. Glucose-6-phos-
phate dehydrogenase deficiency among Yemeni children residing in malaria-endemic areas of Hodei-
dah governorate and evaluation of a rapid diagnostic test for its detection. Malaria journal. 2016;
15:327. https://doi.org/10.1186/s12936-016-1372-9 PMID: 27329471
37. Adu-Gyasi D, Asante KP, Newton S, Dosoo D, Amoako S, Adjei G, et al. Evaluation of the diagnostic
accuracy of CareStart G6PD deficiency Rapid Diagnostic Test (RDT) in a malaria endemic area in
A meta-analysis of the performance of the Access Bio/Care Start RDT for the detection of G6PD deficiency
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002992 December 13, 2019 14 / 15
Ghana, Africa. PloS one. 2015; 10(4):e0125796. https://doi.org/10.1371/journal.pone.0125796 PMID:
25885097
38. Baird JK, Dewi M, Subekti D, Elyazar I, Satyagraha AW. Noninferiority of glucose-6-phosphate dehy-
drogenase deficiency diagnosis by a point-of-care rapid test vs the laboratory fluorescent spot test dem-
onstrated by copper inhibition in normal human red blood cells. Transl Res. 2015; 165(6):677–88.
https://doi.org/10.1016/j.trsl.2014.09.009 PMID: 25312015
39. Alam MS, Kibria MG, Jahan N, Thriemer K, Hossain MS, Douglas NM, et al. Field evaluation of quantita-
tive point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. PloS one. 2018;
13(11):e0206331. https://doi.org/10.1371/journal.pone.0206331 PMID: 30388146
40. Ebstie YA, Abay SM, Tadesse WT, Ejigu DA. Tafenoquine and its potential in the treatment and relapse
prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Devel Ther. 2016; 10:2387–
99. https://doi.org/10.2147/DDDT.S61443 PMID: 27528800
41. Devine A, Parmiter M, Chu CS, Bancone G, Nosten F, Price RN, et al. Using G6PD tests to enable the
safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A
cost-effectiveness analysis. PLoS neglected tropical diseases. 2017; 11(5):e0005602. https://doi.org/
10.1371/journal.pntd.0005602 PMID: 28542194
42. Robinson KM, Yang W, Haidar CE, Hankins JS, Jay DW, Kornegay N, et al. Concordance between glu-
cose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients
with hematologic malignancies. Pharmacogenomics J. 2019; 19(3):305–14. https://doi.org/10.1038/
s41397-018-0043-3 PMID: 30206300
43. Shah SS, Macharia A, Makale J, Uyoga S, Kivinen K, Craik R, et al. Genetic determinants of glucose-6-
phosphate dehydrogenase activity in Kenya. BMC Med Genet. 2014; 15:93. https://doi.org/10.1186/
s12881-014-0093-6 PMID: 25201310
44. Johnson MK, Clark TD, Njama-Meya D, Rosenthal PJ, Parikh S. Impact of the method of G6PD defi-
ciency assessment on genetic association studies of malaria susceptibility. PloS one. 2009; 4(9):e7246.
https://doi.org/10.1371/journal.pone.0007246 PMID: 19789650
45. Alam MS, Kibria MG, Jahan N, Price RN, Ley B. Spectrophotometry assays to determine G6PD activity
from Trinity Biotech and Pointe Scientific G6PD show good correlation. BMC Res Notes. 2018; 11
(1):855. https://doi.org/10.1186/s13104-018-3964-7 PMID: 30514365
A meta-analysis of the performance of the Access Bio/Care Start RDT for the detection of G6PD deficiency
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002992 December 13, 2019 15 / 15
